Synergy CHC Corp. (SNYR) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Synergy CHC Corp. is a consumer health care company focused on building a portfolio of brands, primarily FOCUSfactor (brain health) and Flat Tummy (weight management). The company operates as a non-accelerated filer and smaller reporting company. As of May 13, 2025, there were 9,014,110 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $8,170,534 | $9,411,863 |
| Gross Profit | $6,164,021 | $6,774,724 |
| Gross Margin | 75.4% | 72.0% |
| Net Income | $876,264 | $580,530 |
| EPS (Diluted) | $0.10 | $0.08 |
| EBITDA | $1,979,624 | $1,850,645 |
| Cash & Restricted Cash | $277,882 | $1,010,749 |
| Total Debt (Notes Payable) | $28,119,218 | $27,515,346 |
| Working Capital | $7,340,297 | $(1,124,601) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 13% ($1.24 million) year-over-year. Product sales dropped from $9.41M to $6.67M due to a non-recurring sell-in to a customer in 2024. This was partially offset by $1.5 million in new license revenue.
- Profitability Improvement: Despite lower revenue, Net Income increased 51% to $876,264. This was driven by a 20% reduction in operating expenses (Selling & Marketing and G&A) and a slight improvement in gross margin.
- Cash Flow: Operating cash flow remained negative at $(822,781), an improvement from $(858,042) in Q1 2024. The cash balance decreased significantly from $787,920 to $277,882 due to operating outflows and debt repayments.
- Debt Restructuring: The company consolidated multiple loans with related party Knight Therapeutics into a single facility with a maturity date extended to March 31, 2026. A $1.3 million payment due in Q1 2025 was postponed pending refinancing negotiations.
Outlook, Risks, and Contingencies
- Going Concern: Management has evaluated going concern risks. While the company has an accumulated deficit of $43.2 million, it concluded that substantial doubt is alleviated by a working capital surplus, recent net income, and lender agreements to extend debt maturities.
- Debt Covenants: The company must maintain a minimum quarterly EBITDA of $1.25 million and FOCUSfactor trailing 12-month net sales of $30 million. Failure to raise $5 million in equity by March 31, 2025 (a deadline passed in this filing period) triggers a $1 million fee and potential default, though lenders have agreed to postpone payments.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025.
- Subsequent Events: Post-period, the company repaid $387,115 in principal and $222,861 in interest. Additionally, 442,005 shares were issued to noteholders in lieu of warrants.
Investor Verification Checklist
- Debt Compliance: Verify the status of the $5 million equity raise covenant and the specific terms of the postponed $1.3 million debt payment.
- Revenue Concentration: Confirm the sustainability of revenue given that three customers accounted for 71% of Q1 2025 net revenue.
- Cash Runway: Assess the sufficiency of the $277,882 cash balance against weekly debt repayment obligations (e.g., $81,000/week on the Cedar Advance loan).
- Related Party Transactions: Review the terms of the consolidated loan with Knight Therapeutics, which represents a significant portion of total liabilities ($12.3 million).
- Internal Controls: Investigate the specific deficiencies leading to the ineffective disclosure controls conclusion.